Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Cardlytics, Inc. (CDLX)

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Cardlytics, Inc. (“Cardlytics” or the “Company”) (NASDAQ: CDLX). The investigation concerns whether Cardlytics and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.

[Click here to learn more about the investigation]

On August 7, 2024, Cardlytics reported its financial results for the second quarter ended June 30, 2024, including a decrease of 9% year-over-year in revenue, stating “our results were challenged by slower-than-anticipated billings growth coupled with higher consumer incentives.” The Company also disclosed that Karim Temsamani stepped down as Chief Executive Officer and from the Board of Directors. On this news, the price of Cardlytics shares declined by $3.94 per share, or approximately 57.1%, from $6.90 per share on August 7, 2024 to close at $2.96 on August 8, 2024.

If you purchased or otherwise acquired Cardlytics securities, have information, or would like to learn more about this investigation, contact Thomas W. Elrod of Kirby McInerney LLP by email at [e-mail], or by filling out this CONTACT FORM, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.